Galapagos NV has been awarded a total of €5.2 million in grants from the Netherlands and the EU for the development of drugs for various indications, including bone and joint diseases. Galapagos will collaborate with academic and industrial partners in the grant projects.
The individual grants are:
€2.9 million from the SmartMix programme run by the Dutch Ministries of Economic Affairs and Education, Culture and Science. This will focus on developing new disease models to speed up the drug discovery process in bone and joint diseases;
€1.5 million from the Dutch foundation Top Institute Pharma to identify novel cancer drugs. In this project Galapagos will collaborate with Dutch biotechnology company Agamyxis, the University Medical Center Utrecht and the Hubrecht Institute;
€0.8 million for two projects from the EU’s 6th and 7th Research Framework Programmes, to develop high-throughput assays to study cancer progression and develop anti-cancer compounds in a time and cost effective manner.
“These grants enable us to accelerate our internal discovery activities in bone and joint diseases and also to apply our technologies in other areas of unmet medical need,” said Onno van de Stolpe, CEO of Galapagos.